Please login to the form below

Not currently logged in
Email:
Password:

Roche, Novartis and Bayer gain NICE recommendations

Comes after the Institute effectively shut down for the General Election

National Institute for Health and Care Excellence NICE logo 

Roche, Novartis and Bayer have won new recommendations for their medicines this month but AstraZeneca has seen an early rejection of its new oncology drug. 

First up, Roche has been granted approval for Gazyvaro (obinutuzumab) for patients with chronic lymphocytic leukaemia. 

The drug is a targeted therapy that works by launching a two-pronged attack on cancer cells: it recognises and seeks out the 'enemy' cells and causes them to self-destruct on contact with the drug, while at the same time signalling to the body's own immune system to attack and remove the cell. 

Bayer has also been granted a recommendation for a new licence for its eye disease drug Eylea (aflibercept).

In the draft final appraisal determination NICE recommends Eylea for the treatment of patients with diabetic macular oedema (DMO) - a condition that affects around 50,000 people in the UK. 

This is the third positive NICE recommendation for the drug after receiving its first NICE recommendation for wet age-related macular degeneration back in July 2013.

The second recommendation was for visual impairment due to macular oedema, secondary to central retinal vein occlusion (CRVO), which came in February last year. 

Meanwhile Novartis' Cosentyx (secukinumab) has also been given final approval as the first in a new generation of psoriasis treatments.

Specifically, the drug is recommended as an option for treating some adults with plaque psoriasis if they are unable to take standard systemic therapies and if the drug is provided with the agreed patient access scheme discount, which cuts the overall cost of the medicine to the NHS.

But it has not been good news as AstraZeneca's new cancer drug Lynparza (olaparib) has been rejected by the watchdog.

In preliminary draft guidance, NICE is saying no for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube and peritoneal cancer. 

The drug is for cancers in people who have tested positive for the BRCA1 or BRCA2 mutations, and whose disease has responded to second-line or subsequent platinum-based chemotherapy.

NICE says that the price it is being asked to pay for the drug “is too high for the benefit it may provide to patients”, so the preliminary guidance does not recommend it. The drug has five main EU licences, but BICE has yet to recommend the drug for NHS funding for any of them.

This draft guidance is now open for public consultation.

These decisions come after NICE effectively shut down during the UK General Election between late March and May. 

Article by
Ben Adams

2nd June 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics